{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:49:19Z","timestamp":1791481759970,"version":"4.3.4"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"DOI":"10.1038\/s41433-026-04976-2","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:51:15Z","timestamp":1791478275000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined limbal dysmaturation and microcyst like epithelial changes with corneal nerve alterations of a novel anti nectin-4-MMAE antibody drug conjugate"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8714-3060","authenticated-orcid":false,"given":"Marwa","family":"Deiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Pobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Uliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaissa","family":"Ouali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Labetoulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2355-2804","authenticated-orcid":false,"given":"Antoine","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"4976_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2024.101302","volume":"103","author":"EE Gabison","year":"2024","unstructured":"Gabison EE, Rousseau A, Labetoulle M, Gazzah A, Besse B. Ocular adverse events associated with antibody-drug conjugates used in cancer: focus on pathophysiology and management strategies. Prog Retin Eye Res. 2024;103:101302. https:\/\/doi.org\/10.1016\/j.preteyeres.2024.101302.","journal-title":"Prog Retin Eye Res"},{"key":"4976_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217681","volume":"622","author":"M Nikanjam","year":"2025","unstructured":"Nikanjam M, P\u00e9rez-Granado J, Gramling M, Larvol B, Kurzrock R. Nectin-4 expression patterns and therapeutics in oncology. Cancer Lett. 2025;622:217681. https:\/\/doi.org\/10.1016\/j.canlet.2025.217681.","journal-title":"Cancer Lett"},{"key":"4976_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/ICO.0000000000001526","volume":"37","author":"N Okumura","year":"2018","unstructured":"Okumura N, Kagami T, Fujii K, Nakahara M, Koizumi N. Involvement of nectin-afadin in the adherens junctions of the corneal endothelium. Cornea. 2018;37:633\u201340. https:\/\/doi.org\/10.1097\/ICO.0000000000001526.","journal-title":"Cornea"},{"key":"4976_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bbrc.2009.08.130","volume":"389","author":"R Kusanagi","year":"2009","unstructured":"Kusanagi R, Umemoto T, Yamato M, Matsuzaki Y, Nishida K, Kobayashi Y, et al. Nectin-3 expression is elevated in limbal epithelial side population cells with strongly expressed stem cell markers. Biochem Biophys Res Commun. 2009;389:274\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2009.08.130.","journal-title":"Biochem Biophys Res Commun"},{"key":"4976_CR5","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.3390\/ijms26114996","volume":"26","author":"J Zhang","year":"2025","unstructured":"Zhang J, Li M, Li W, Yang Y, Wu G, Guo P, et al. Mechanistic insights into anti-nectin4-VcMMAE-induced ocular toxicity: from cellular uptake pathways to molecular modification. Int J Mol Sci. 2025;26:4996 https:\/\/doi.org\/10.3390\/ijms26114996.","journal-title":"Int J Mol Sci"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04976-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04976-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04976-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:51:21Z","timestamp":1791478281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04976-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":5,"alternative-id":["4976"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04976-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MD, RB, and JU: nothing to declare. CP reports receiving honoraria from Merck and Johnson & Johnson, as well as travel grants and invitations from Amgen, AstraZeneca, Bayer, Eisai, Ipsen, Janssen-Cilag, MSD, Pfizer, Sandoz, Sanofi, Seagen France and Vifor. As part of the Drug Development Department (DITEP), he reports serving as a principal or sub-investigator of clinical trials for Abbvie, Adaptimmune, Adlai Nortye USA Inc, Aduro Biotech, Agios Pharmaceuticals, Amgen, Astra Zeneca Ab, Astra Zeneca, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, Beigene, BicycleTx Ltd, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Casi Pharmaceuticals, Inc, Cato Research, Celgene Corporation, Cellcentric, Chugai Pharmaceutical Co, Corbus, Cullinan-Apollo, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, EverImmune, Exelixis, Faron Pharmaceuticals Ltd, Foghorn Therapeutics Inc, Forma Tharapeutics, Gamamabs, Genentech, Genmab, Glaxosmithkline, H3 Biomedicine, Hoffmann La Roche Ag, IGM Biosciences, Imcheck Therapeutics, Incyte Corporation, Innate Pharma, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Janssen R&D LLC, johnson & johnson, K-Group Beta, Kinnate Biopharma, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merus, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Nuvalent, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Phio Pharmaceuticals Corp, Pierre Fabre Medicament, Pyramid Bioscience, Regeneron Pharmaceuticals, Relay Therapeutics, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Transgene S.A, Turning Point Therapeutics and Xencor. He also reports research grants from AstraZeneca, BMS, Boehringer Ingelheim, Celsius, EIT Philips, GSK, IDERA, INCA, Janssen, Lombard, MedImmune, Merck, Pierre Fabre, Roche, Sanofi and Servier, and non-financial support (drug supplied) from AstraZeneca, BMS, Boehringer Ingelheim, GSK, Idera, MedImmune, Merck, NH Theraguix and Roche. YL reports research funding from Astellas, Amgen, OBS and PMV. He reports consulting or advisory roles for Janssen, MSD, Pfizer, Astellas, Roche and AstraZeneca. He also reports receiving honoraria from Janssen, MSD, Pfizer, Astellas, Roche and AstraZeneca, as well as travel, accommodation or expense support from Janssen, MSD, Pfizer, Astellas and AstraZeneca. KO reports serving as a sub-investigator for the clinical trial of CRB 701. ML serves as an occasional consultant for GSK, Novartis, and AbbVie. AR serves as an occasional consultant for GSK, Novartis, AbbVie, AstraZeneca, Genmab. The other authors have no conflict of interest in relationship with this study.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}